Testing the addition of an antiangiogenic drug (bevacizumab) to chemotherapy (carboplatin and paclitaxel) combined with immunotherapy (pembrolizumab) for pMMR, TP53 mutated endometrial cancer

Full Title

A Randomized Phase III Trial of Carboplatin, Paclitaxel, Pembrolizumab Versus Carboplatin, Paclitaxel, Bevacizumab Versus Carboplatin, Paclitaxel, Pembrolizumab, Bevacizumab in the Treatment of pMMR, TP53 Mutated Advanced or Recurrent Endometrial Cancer (NRG-GY035) (CIRB)

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Carol Aghajanian’s office at 646-888-4217.